Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Infectious Diseases and Therapy
Published in: Infectious Diseases and Therapy 4/2017

Open Access 01-12-2017 | Review

New Viral and Immunological Targets for Hepatitis B Treatment and Cure: A Review

Authors: Joop E. Arends, Faydra I. Lieveld, Shazaad Ahmad, Andrew Ustianowski

Published in: Infectious Diseases and Therapy | Issue 4/2017

Login to get access

Abstract

Although current therapies can be successful at suppressing hepatitis B viral load, long-term viral cure is not within reach. Subsequent strategies combining pegylated interferon alfa with nucleoside/nucleotide analogues have not resulted in any major paradigm shift. An improved understanding of the hepatitis B virus (HBV) lifec ycle and virus-induced immune dysregulation has, however, revealed many potential therapeutic targets, and there are hopes that treatment of hepatitis B could soon be revolutionized. This review summarizes the current developments in HBV therapeutics—both virus directed and host directed.
Literature
1.
World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization; 2015.
2.
Fattovich G. Natural history and prognosis of hepatitis B. Semin Liv Dis. 2003;23(1):47–58.
3.
Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006;43(2 Suppl 1):S173–81.
4.
McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49(5 Suppl):S45–55.
5.
Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol. 1997;71:9392–9.PubMedPubMedCentral
6.
Wong DK-H, Seto W-K, Fung J, Ip P, Huang F-Y, Lai C-L, et al. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. Clin Gastroenterol Hepatol. 2013;11:1004–10.CrossRefPubMed
7.
Terrault NA, Bzowej NH, Chang K, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261–83.CrossRefPubMed
8.
Noell BC, Besur SV. Changing the face of hepatitis C management – the design and development of sofosbuvir. Drug Des Dev Ther. 2015;9:2367.
9.
10.
Eggink D, Berkhout B, Sanders RW. Inhibition of HIV-1 by fusion inhibitors. Curr Pharm Des. 2010;16:3716–28.CrossRefPubMed
11.
Sun J, Xie Q, Tan D, Ning Q, Niu J, Bai X, et al. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. Hepatology. 2014;59:1283–92.CrossRefPubMed
12.
Micco L, Peppa D, Loggi E, Schurich A, Jefferson L, Cursaro C, et al. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol. 2013;58:225–33.CrossRefPubMed
13.
Buster EHCJ, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon α-2b. Gastroenterology. 2008;135:459–67.CrossRefPubMed
14.
Lau GKK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682–95.CrossRefPubMed
15.
Brouwer WP, Xie Q, Sonneveld MJ, Zhang N, Zhang Q, Tabak F, et al. Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: a multicenter randomized trial (ARES study). Hepatology. 2015;61:1512–22.CrossRefPubMed
16.
Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, et al. Switching from entecavir to pegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomized open-label trial (OSST trial). J Hepatol. 2014;61:777–84.CrossRefPubMed
17.
Janssen HLA, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365:123–9.CrossRefPubMed
18.
Marcellin P, Ahn SH, Ma X, Caruntu FA, Tak WY, Elkashab M, et al. Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology. 2016;150(134–144):e10.
19.
Xie Q, Zhou H, Bai X, Wu S, Chen J-J, Sheng J, et al. A randomized, open-label clinical study of combined pegylated interferon alfa-2a (40KD) and entecavir treatment for hepatitis B “e” antigen-positive chronic hepatitis B. Clin Infect Dis. 2014;59:1714–23.CrossRefPubMed
20.
Bourliere M, Rabiega P, Ganne-Carrie N, Serfaty L, Marcellin P, Pouget N, et al. HBsAg clearance after addition of 48 weeks of PEGIFN in HBeAg negative CHB patients on nucleos(t)ide therapy with undetectable HBV DNA for at least one year: a multicenter randomized controlled phase III trial ANRS-HB06 PEGAN study: preliminary findings. Hepatology. 2014;60:1094A–5A.
21.
Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012;1:e00049.CrossRefPubMedPubMedCentral
22.
Blank A, Markert C, Hohmann N, Carls A, Mikus G, Lehr T, et al. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol. 2016;65:483–9.CrossRefPubMed
23.
Volz T, Allweiss L, ḾBarek MB, Warlich M, Lohse AW, Pollok JM, et al. The entry inhibitor myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol. 2013;58:861–7.
24.
Zimmerman KA, Fischer KP, Joyce MA, Tyrrell DLJ. Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture. J Virol. 2008;82:8013–21.CrossRefPubMedPubMedCentral
25.
Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother. 2012;67:1607–15.CrossRefPubMed
26.
Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014;343:1221–8.CrossRefPubMed
27.
Dong C, Qu L, Wang H, Wei L, Dong Y, Xiong S. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. Antivir Res. 2015;118:110–7.CrossRefPubMed
28.
Liu X, Hao R, Chen S, Guo D, Chen Y. Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome. J Gen Virol. 2015;96:2252–61.CrossRefPubMed
29.
Kennedy EM, Bassit LC, Mueller H, Kornepati AVR, Bogerd HP, Nie T, et al. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology. 2015;476:196–205.CrossRefPubMed
30.
Gish RG, Given BD, Lai C-L, Locarnini SA, Lau JYN, Lewis DL, et al. Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities. Antiviral Res. 2015;121:47–58.CrossRefPubMed
31.
Yuen M-F, Chan HLY, Liu K, Given BD, Schluep T, Hamilton J, et al. Differential reductions in viral antigens expressed from CCCDNAVS integrated DNA in treatment naïve HBEAG positive and negative patients with chronic HBV after RNA interference therapy with ARC-520. J Hepatol. 2016;64:S390–1.CrossRef
32.
Sepp-Lorenzino L, Sprague AG, Mayo T. Parallel 4: hepatitis B: novel treatments and treatment targets: 36—GalNAc-siRNA conjugate ALN-HBV targets a highly conserved, pan-genotypic X-orf viral site and mediates profound and durable HBsAg silencing in vitro and in vivo. Hepatology. 2015;62:222A–5A.CrossRef
33.
Billioud G, Kruse RL, Carrillo M, Whitten-Bauer C, Gao D, Kim A, et al. In vivo reduction of hepatitis B virus antigenemia and viremia by antisense oligonucleotides. J Hepatol. 2016;64:781–9.CrossRefPubMed
34.
Mani N, Cole AG, Ardzinski A, Cai D, Cuconati A, Dorsey BD, et al. The HBV capsid inhibitor AB-423 exhibits a dual mode of action and displays additive/synergistic effects in in vitro combination studies. Hepatology. 2016;64(Suppl S1):123A–4A.
35.
Berke JM, Dehertogh P, Vergauwen K, van Damme E, Raboisson P, Pauwels F, et al. Capsid assembly modulator JNJ-56136379 prevents de novo infection of primary human hepatocytes with hepatitis B virus. Hepatology. 2016;64(Suppl S1):124A.
36.
Stray SJ, Zlotnick A. BAY 41‐4109 has multiple effects on hepatitis B virus capsid assembly. J Mol Recognit. 2006;19:542–8.CrossRefPubMed
37.
Yuen M-F, Kim DJ, Weilert F, Chan HL-Y, Lalezari JP, Hwang SG, et al. Phase 1b efficacy and safety of NVR 3-778, a first-in-class HBV core inhibitor, in HBeAg-positive patients with chronic HBV infection. Hepatology. 2015;62:1385A–6A.
38.
Yuen M-F, Kim DJ, Weilert F, Chan H-Y, Lalezari JP, Hwang SG, et al. NVR 3-778, a first-in-class HBV core inhibitor, alone and in combination with peg-interferon (pegIFN), in treatment-naive HBeAg-positive patients: early reductions in HBV DNA and HBeAg. J Hepatol. 2016;64:S210–1.CrossRef
39.
Decorsiere A, Mueller H, Van Breugel PC, Abdul F, Gerossier L, Beran RK, et al. Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor. Nature. 2016;531:386–406.CrossRefPubMed
40.
Painter GR, Almond MR, Trost LC, Lampert BM, Neyts J, De Clercq E, et al. Evaluation of hexadecyloxypropyl-9-R-[2-(phosphonomethoxy) propyl]-adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. Antimicrob Agents Chemother. 2007;51:3505–9.CrossRefPubMedPubMedCentral
41.
Michalak TI, Zhang H, Churchill ND, Larsson T, Johansson N-G, Öberg B. Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis B. Antimicrob Agents Chemother. 2009;53:3803–14.CrossRefPubMedPubMedCentral
42.
Bazinet M, Pantea V, Cebotarescu V, Cojuhari L, Jimbei P, Albrecht J, et al. Initial follow up results from the REP 301 trial: safety and efficacy of REP 2139-Ca and pegylated interferon alpha-2a in caucasian patients with chronic HBV/HDV co-infection. In: Hepatology. 2016;64(Suppl S1):912A.
43.
Bazinet M, Pantea V, Cebotarescu V, Cojuhari L, Jimbei P, Albrecht J, et al. Update on the safety and efficacy of REP 2139 monotherapy and subsequent combination therapy with pegylated interferon alpha-2A in Caucasian patients with chronic HBV/HDV co-infection. J Hepatol. 2016;64:S584–5.CrossRef
44.
Bertoletti A, Gehring AJ. The immune response during hepatitis B virus infection. J Gen Virol. 2006;87:1439–49.CrossRefPubMed
45.
Luckheeram RV, Zhou R, Verma AD, Xia B. CD4+T cells: differentiation and functions. Clin Dev Immunol. 2012;2012:925135.
46.
Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, et al. CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol. 2003;77:68–76.CrossRefPubMedPubMedCentral
47.
von Andrian UH, Mackay CR. T-cell function and migration—two sides of the same coin. N Engl J Med. 2000;343:1020–34.CrossRef
48.
49.
50.
51.
Zhu Y. Immune checkpoint drug goes viral: developing new treatment paradigm for chronic viral infection. J Hum Virol Retroviral. 2014;1:4.
52.
53.
Maini MK, Schurich A. The molecular basis of the failed immune response in chronic HBV: therapeutic implications. J Hepatol. 2010;52:616–9.CrossRefPubMed
54.
Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut. 2012;61:1754–64.CrossRefPubMed
55.
Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006–17.CrossRefPubMed
56.
57.
Hotchkiss RS, Moldawer LL. Parallels between cancer and infectious disease. N Engl J Med. 2014;371:380–3.CrossRefPubMed
58.
Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol. 2007;81:4215–25.CrossRefPubMedPubMedCentral
59.
Fisicaro P, Valdatta C, Massari M, Loggi E, Ravanetti L, Urbani S, et al. Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV. Gastroenterology. 2012;143:1576–85.CrossRefPubMed
60.
Blackburn SD, Crawford A, Shin H, Polley A, Freeman GJ, Wherry EJ. Tissue-specific differences in PD-1 and PD-L1 expression during chronic viral infection: implications for CD8 T-cell exhaustion. J Virol. 2010;84:2078–89.CrossRefPubMed
61.
Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–9.CrossRefPubMed
62.
Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013;98:1361–75.CrossRefPubMed
63.
Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ B. 2015;35:76–83.CrossRef
64.
65.
Fosdick A, Zheng J, Pflanz S, Frey CR, Hesselgesser J, Halcomb RL, et al. Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. J Pharmacol Exp Ther. 2014;348:96–105.CrossRefPubMed
66.
Gane EJ, Lim Y-S, Gordon SC, Visvanathan K, Sicard E, Fedorak RN, et al. The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. J Hepatol. 2015;63:320–8.CrossRefPubMed
67.
Janssen HL, Brunetto MR, Kim YJ, Ferrari C, Massetto B, Nguyen A-H, et al. Safety and efficacy of GS-9620 in Virally-suppressed patients with chronic hepatitis B. Hepatology. 2016;64(Suppl S1):913A–4A.
68.
Boni C, Vecchi A, Rossi M, Laccabue D, Giuberti TG, Alfieri A, et al. TLR-7 agonist GS-9620 can improve HBV-specific T cell and NK cell responses in nucleos(t)ide suppressed patients with chronic hepatitis B. Hepatology. 2016;64(Suppl S1):7A.
69.
Lanford RE, Guerra B, Chavez D, Giavedoni L, Hodara VL, Brasky KM, et al. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology. 2013;144:1508–17.CrossRefPubMedPubMedCentral
70.
Menne S, Tumas DB, Liu KH, Thampi L, AlDeghaither D, Baldwin BH, et al. Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B. J Hepatol. 2015;62:1237–45.CrossRefPubMedPubMedCentral
71.
Jo J, Tan AT, Ussher JE, Sandalova E, Tang X-Z, Tan-Garcia A, et al. Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver. PLoS Pathog. 2014;10:e1004210.CrossRefPubMedPubMedCentral
72.
Deng G, Ge J, Liu C, Pang J, Huang Z, Peng J, et al. Impaired expression and function of TLR8 in chronic HBV infection and its association with treatment responses during peg-IFN-α-2a antiviral therapy. Clin Res Hepatol Gastroenterol. 2017;41:386–39.
73.
Gaggar A, Coeshott C, Apelian D, Rodell T, Armstrong BR, Shen G, et al. Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study. Vaccine. 2014;32:4925–31.CrossRefPubMed
74.
Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, et al. The role of virus-specific CD8+ cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med. 2000;191:1269–80.CrossRefPubMedPubMedCentral
75.
Webster GJM, Reignat S, Brown D, Ogg GS, Jones L, Seneviratne SL, et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol. 2004;78:5707–19.CrossRefPubMedPubMedCentral
76.
Boni C, Rossi M, Vecchi A, Laccabue D, Giuberti T, Alfieri A, et al. PS-050 - combined GS-4774 and tenofovir therapy can improve HBV-specific T cell responses in patients with chronic active hepatitis B. J Hepatol. 2017;66:S29.CrossRef
77.
Bian Y, Zhang Z, Sun Z, Zhao J, Zhu D, Wang Y, et al. Vaccines targeting PreS1 domain overcome immune tolerance in HBV carrier mice. Hepatology. 2017;66:1067–82.
78.
Wedemeyer H, Hui AJ, Sukeepaisarnjaroen W, Tangkijvanich P, Su WW, Nieto GEG, et al. LBP-518 - therapeutic vaccination of chronic hepatitis B patients with ABX203 (NASVAC) to prevent relapse after stopping NUCs: contrasting timing rebound between tenofovir and entecavir. J Hepatol. 2017;66:S101.CrossRef
79.
Liu J, Kosinska A, Lu M, Roggendorf M. New therapeutic vaccination strategies for the treatment of chronic hepatitis B. Virol Sin. 2014;29:10–6.CrossRefPubMed
80.
Gane E, Gaggar A, Nguyen AH, Subramanian GM, McHutchison JG, Schwabe C, et al. PS-044 - a phase1 study evaluating anti-PD-1 treatment with or without GS-4774 in HBeAg negative chronic hepatitis B patients. J Hepatol. 2017;66:S26–7.CrossRef
81.
Piccolo P, Lenci I, di Paolo D, Demelia L, Sorbello O, Nosotti L, et al. A randomized controlled trial of sequential pegylated interferon-alpha and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther. 2013;18:57–64.CrossRefPubMed
82.
Liu Y-H, Wu T, Sun N, Wang G-L, Yuan J-Z, Dai Y-R, et al. Combination therapy with pegylated interferon alpha-2b and adefovir dipivoxil in HBeAg-positive chronic hepatitis B versus interferon alone: A prospective, randomized study. J Huazhong Univ Sci Technol Med Sci. 2014;34:542–7.CrossRefPubMed
83.
Tangkijvanich P, Chittmittraprap S, Poovorawan K, Limothai U, Khlaiphuengsin A, Chuaypen N, et al. A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: role of host and viral factors associated with treatment response. J Viral Hepat. 2016;23:427–38.
84.
Marcellin P, Wursthorn K, Wedemeyer H, Chuang W-L, Lau G, Avila C, et al. Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. J Hepatol. 2015;62:41–7.CrossRefPubMed
Metadata
Title
New Viral and Immunological Targets for Hepatitis B Treatment and Cure: A Review
Authors
Joop E. Arends
Faydra I. Lieveld
Shazaad Ahmad
Andrew Ustianowski
Publication date
01-12-2017
Publisher
Springer Healthcare
Published in
Infectious Diseases and Therapy / Issue 4/2017
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-017-0173-y

Other articles of this Issue 4/2017

Infectious Diseases and Therapy 4/2017 Go to the issue

Original Research

Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R + Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical Trials

Original Research

Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States

Protocol

Interventions Targeting the Prescribing and Monitoring of Vancomycin for Hospitalized Patients: A Systematic Review Protocol

Original Research

Assessments of Opportunities to Improve Antibiotic Prescribing in an Emergency Department: A Period Prevalence Survey

Original Research

Efficacy of Conventional and Liposomal Povidone–Iodine in Infected Mesh Skin Grafts: An Exploratory Study

Original Research

Time–Kill Analysis of Ceftolozane/Tazobactam Efficacy Against Mucoid Pseudomonas aeruginosa Strains from Cystic Fibrosis Patients

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits